SOURCE: Theravance, Inc.

August 29, 2006 16:05 ET

Theravance Announces Upcoming Schedule of Investor Conferences in September 2006

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- August 29, 2006 -- Theravance, Inc. (NASDAQ: THRX) announced today that management is scheduled to present at several investor conferences in September:

Thomas Weisel Partners
Thomas Weisel Partners Annual Healthcare Conference
The Four Seasons Hotel, Boston, Massachusetts
Thursday, September 7, 2006
6:10 a.m. PDT/9:10 a.m. EDT
Rick E Winningham, Chief Executive Officer

Bear Stearns
Bear Stearns 19th Annual Healthcare Conference
The Grand Hyatt, New York, New York
Tuesday, September 12, 2006
8:30 PDT/11:30 EDT
Michael W. Aguiar, Senior Vice President and Chief Financial Officer

Merrill Lynch
Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference 2006
Merrill Lynch Financial Centre, London, England
Wednesday, September 20, 2006
3:20 p.m. BST/7:20 a.m. PDT/10:20 a.m. EDT
Rick E Winningham, Chief Executive Officer

Prudential Equity Group
Mid-west Healthcare Investor Day
InterContinental Hotel, Chicago, Illinois
Thursday, September 21, 2006
Michael W. Aguiar, Senior Vice President and Chief Financial Officer
All webcast information will be available on Theravance's web site at Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Of the five programs in development, two are in late stage -- its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas Pharma Inc. and the Beyond Advair collaboration with GlaxoSmithKline. By leveraging its proprietary insight of multivalency to drug discovery focused on validated targets, Theravance is pursuing a next generation drug discovery strategy designed to discover superior medicines in large markets. For more information, please visit the company's web site at

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

Theravance's presentations will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to the goals, timing and expected results of clinical studies, statements regarding the potential benefits and mechanisms of action of drug candidates, the enabling capabilities of Theravance's approach to drug discovery and its proprietary insights, statements concerning expectations for product candidates through development and commercialization and projections of revenue and other financial items. These statements are based on the current estimates and assumptions of the management of Theravance as of the dates of the respective presentations and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to delays or difficulties in commencing or completing clinical and preclinical studies, the potential that results of clinical or preclinical studies indicate product candidates are unsafe, ineffective, inferior or not superior, and delays or failure to achieve regulatory approvals, and risks of collaborating with third parties to develop and commercialize products. These and other risks are described in greater detail under the heading "Risk Factors" contained in Item 1A of Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2006 and the risks discussed in our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements.

Contact Information

  • Contact Information:
    Theravance, Inc.
    Allison Parker
    Director, Investor Relations
    Email Contact

    Theravance, Inc.
    David Brinkley
    SVP, Commercial Development
    Email Contact